{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:34:23Z","timestamp":1793144063550,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13504-6","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:20:27Z","timestamp":1737534027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations"],"prefix":"10.1186","volume":"25","author":[{"given":"Masato","family":"Kikuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Numakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Narisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ojiro","family":"Tokairin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"11","key":"13504_CR1","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/cncr.34180","volume":"128","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barth\u00e9l\u00e9my P, Plimack ER, Porta C, George S, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128(11):2085\u201397.","journal-title":"Cancer"},{"issue":"8","key":"13504_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","volume":"31","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030\u20139.","journal-title":"Ann Oncol"},{"issue":"5","key":"13504_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","volume":"84","author":"ER Plimack","year":"2023","unstructured":"Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Souli\u00e8res D, et al. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. Eur Urol. 2023;84(5):449\u201354.","journal-title":"Eur Urol"},{"issue":"5","key":"13504_CR4","doi-asserted-by":"publisher","first-page":"102994","DOI":"10.1016\/j.esmoop.2024.102994","volume":"9","author":"T Powles","year":"2024","unstructured":"Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, Su\u00e1rez C, Porta C, Barrios CH, Richardet M, et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO open. 2024;9(5):102994.","journal-title":"ESMO open"},{"issue":"11","key":"13504_CR5","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024;42(11):1222\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"13504_CR6","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir NM, Albig\u00e8s L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barth\u00e9l\u00e9my P, Plimack ER, Porta C, George S, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024;35(11):1026\u201338.","journal-title":"Ann Oncol."},{"issue":"4","key":"13504_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2019.10.025","volume":"77","author":"B Escudier","year":"2020","unstructured":"Escudier B, Motzer RJ, Tannir NM, Porta C, Tomita Y, Maurer MA, McHenry MB, Rini BI. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol. 2020;77(4):449\u201353.","journal-title":"Eur Urol"},{"issue":"34","key":"13504_CR8","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794\u20139.","journal-title":"J Clin Oncol"},{"key":"13504_CR9","doi-asserted-by":"publisher","first-page":"175883592110196","DOI":"10.1177\/17588359211019642","volume":"13","author":"SE Rebuzzi","year":"2021","unstructured":"Rebuzzi SE, Signori A, Banna GL, Maruzzo M, De Giorgi U, Pedrazzoli P, Sbrana A, Zucali PA, Masini C, Naglieri E, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther Adv Med Oncol. 2021;13:17588359211019642.","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"13504_CR10","doi-asserted-by":"publisher","first-page":"100634","DOI":"10.1016\/j.esmoop.2022.100634","volume":"7","author":"SE Rebuzzi","year":"2022","unstructured":"Rebuzzi SE, Signori A, Buti S, Banna GL, Murianni V, Damassi A, Maruzzo M, Giannarelli D, Tortora G, Galli L, et al. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. ESMO open. 2022;7(6):100634.","journal-title":"ESMO open"},{"issue":"1","key":"13504_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1186\/s12885-024-12319-1","volume":"24","author":"SE Rebuzzi","year":"2024","unstructured":"Rebuzzi SE, Fornarini G, Signori A, Buti S, Procopio G, De Giorgi U, Pignata S, Naglieri E, Maruzzo M, Banna GL, et al. International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study). BMC Cancer. 2024;24(1):757.","journal-title":"BMC Cancer"},{"issue":"10","key":"13504_CR12","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s10147-021-01979-9","volume":"26","author":"S Naito","year":"2021","unstructured":"Naito S, Kato T, Numakura K, Hatakeyama S, Koguchi T, Kandori S, Kawasaki Y, Adachi H, Kato R, Narita S, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. Int J Clin Oncol. 2021;26(10):1947\u201354.","journal-title":"Int J Clin Oncol."},{"issue":"14","key":"13504_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"3","key":"13504_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2022.10.017","volume":"83","author":"KN Fitzgerald","year":"2023","unstructured":"Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, et al. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. Eur Urol. 2023;83(3):195\u20139.","journal-title":"Eur Urol"},{"issue":"5","key":"13504_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/iju.15396","volume":"31","author":"Y Matsushita","year":"2024","unstructured":"Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, et al. Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. Int J Urol. 2024;31(5):526\u201333.","journal-title":"Int J Urol"},{"issue":"4","key":"13504_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10147-024-02471-w","volume":"29","author":"H Ishihara","year":"2024","unstructured":"Ishihara H, Omae K, Nemoto Y, Ishiyama R, Tachibana H, Nishimura K, Ikeda T, Kobari Y, Fukuda H, Yoshida K, et al. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data. Int J Clin Oncol. 2024;29(4):473\u201380.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"13504_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.euo.2023.07.003","volume":"7","author":"M Santoni","year":"2024","unstructured":"Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, et al. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? European urology oncology. 2024;7(1):102\u201311.","journal-title":"European urology oncology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13504-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T20:11:45Z","timestamp":1737576705000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13504-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13504"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13504-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Hokkaido University approved this study (Approval no, 023\u20130105). Informed consent was waved by using the opt-out method for this retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sei Naito received honoraria from Pfizer Japan Inc., Merk biopharma Japan Inc., Bristol Meier\u2019s squibb Japan Inc., Ono Pharma, MSD Japan, and Eisai Co. as their sponsored speaker. Takahiro Osawa received honoraria from MSD Japan. Nobuo Shinohara received honoraria from Pfizer, Ono, BMS, MSD, Takeda, Novartis, Eisai, Astra Zeneca, Bayer, Astellas, as their sponsored speaker and research funds from Ono and Takeda. Tomonori Habuchi received honoraria from Astellas, Ono, Janssen, as their sponsored speaker, and research funds from Sysmex and Mochida. Norihiko Tsuchiya received honoraria from Pfizer Japan Inc. Janssen, Novartis, Ono, Bayer, Sanofi, Takeda Pharm, Bristol-Myers Squibb Japan, and Astelas Pharma., as their sponsored speaker and research funds from Pfizer Japan Inc. and Eisai outside the submitted work. The other authors have declared that no conflict of interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}